A biosimilar transition policy came into effect in Ontario on March 31, 2023. The objective of this webinar is to increase knowledge about biosimilars in general, and biosimilar insulins in particular, and to help pharmacists implement a structured approach to assess the clinical situation of their type 2 diabetes patients in order to facilitate this transition.
While this activity focuses on the Ontario context, it is relevant to all pharmacists practicing in a province where a biosimilar transition policy may be implemented in the future.